Twist Bioscience Announces Partnership with Eli Lilly's TuneLab, Driving Significant Stock Gains
On September 15, 2026, Twist Bioscience (NASDAQ: TWST) announced a partnership to provide antibody characterization data services for Eli Lilly’s AI-driven drug discovery platform, TuneLab. This collaboration allows Twist to leverage its AbLab model and contribute high-quality data back into the system used by pharmaceutical researchers globally. The news sent Twist's stock soaring more than 31% over the week as investors reacted positively to the strategic alliance with a major player in biotechnology. The partnership is seen as mutually beneficial, enhancing TuneLab’s capabilities while providing revenue and research opportunities for Twist Bioscience.
Topics: AI biotech drug_discovery partnership